semaglutide clinical trials SELECT Trial Frontiers | Semaglutide in cognitive

Human data (from a meta-analysis of 894 participants) show fenugreek supplementation (0.5 g to 10 g daily over 4 weeks to 6 months) reduces fasting glucose, post-meal glucose, and HbA1c

Chromium (as Chromium Picolinate) 1000 mcg (2,857% DV)

Store 20 C dry;

Telehealth provider AgelessRX focuses on anti-aging treatments and includes GLP-1 prescriptions as part of its programs

A collage of various food items and grocery scenes, including fresh produce, packaged goods, and a shopping basket

- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026